NCI Budget Increase Keeps 5-Year Doubling in Sight

Publication
Article
OncologyONCOLOGY Vol 14 No 8
Volume 14
Issue 8

Sen. Mack has been cochair of the Senate Cancer Coalition, so he was also quite happy that the Senate approved a National Institutes of Health budget for fiscal year 2001 (starting October 1) that would be a $2.7 billion increase over the

Sen. Connie Mack (R-FL), cochair of the Senate Cancer Coalition, was quite happy that the Senate approved a National Institutes of Health budget for fiscal year 2001 (starting October 1) that would be a $2.7 billion increase over the current year. The NCI budget would increase to $3.3 billion. This puts the NCI on track to double its budget over 5 years, which Vice President Gore advocated in June. While Gore emphasized the importance of NCI funding on research, he also highlighted the need to improve early detection, backing a new “fast track” Medicare approval for cutting-edge prevention and detection benefits. “Medicare still does not cover some prevention benefits, such as some common prostate cancer screenings,” he said. Nevertheless, Medicare is in the process of reducing reimbursements for some types of cancer screenings. Some mammography screening centers will be in tough shape soon, according to the American Medical Association (AMA), which says Medicare wants to reduce the payment for bilateral diagnostic mammography from $50.89 to $33.94. Yank Coble, md, a member of the AMA board of directors, told a House hearing that the decrease is compounded by the new outpatient bundling payment schedule, which makes the payment the same whether the mammogram is of one breast or both breasts. “The threat to access to mammography services is very clear and quite disturbing,” he emphasized.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.